Management of Bone Disease and Body Composition Changes
Summary
- In the ANRS CO4 substudy, no association was found between tenofovir DF and fracture risk[Costagliola 2017]
- In the STEAL study, 360 virologically suppressed patients were randomized to switch their current NRTIs to either abacavir/lamivudine or emtricitabine/tenofovir DF
- No significant change in hip or spine T scores were observed in the abacavir/lamivudine arm, but BMD at both sites decreased in the emtricitabine/tenofovir DF arm[Martin 2009]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Bone Disease , Treatment Complications